Stocks and Investing
Stocks and Investing
Wed, May 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BNTX) at Hold with Decreased Target to $195 on, May 10th, 2022
Matthew Harrison of Morgan Stanley, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $197 to $195 on, May 10th, 2022.
Matthew has made no other calls on BNTX in the last 4 months.
There are 4 other peers that have a rating on BNTX. Out of the 4 peers that are also analyzing BNTX, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $200 on, Friday, April 1st, 2022
- Simon Baker of "Redburn Partners" Upgraded from Strong Sell to Hold on, Tuesday, February 1st, 2022
These are the ratings of the 2 analyists that currently disagree with Matthew
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $298 on, Tuesday, April 12th, 2022
- Arlinda Lee of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $300 on, Tuesday, April 5th, 2022
Contributing Sources